Intravitreal injection therapy in the treatment of noninfectious uveitis

Giulio Modorati, Elisabetta Miserocchi

Research output: Chapter in Book/Report/Conference proceedingChapter


Uveitis is responsible for 5-20% of legal blindness in the United States and in Europe. In noninfectious uveitis, the most frequent uveitic complication that endangers sight is cystoid macular edema. Clinical characteristics, inflammation grading and visual acuity determine the choice of the correct therapy for each patient. We can utilize drugs either alone or in combination using different dosages and routes of administration. Intravitreal injection directly into the vitreous cavity leads to rapid therapeutic drug concentration in the retinal tissue and reduces systemic side effects. Intravitreally injected triamcinolone acetonide is the most powerful drug for the treatment of cystoid macular edema related to intraocular inflammation, but it also causes the most frequent and serious side effects. Due to the numerous side effects associated with the use of corticosteroids, there is a need to identify other anti-inflammatory agents with a better safety profile. Recent studies have demonstrated that intravitreal immunosuppressant injections of methotrexate or anti-VEGF agents may lead to fewer intraocular side effects, but also have a lower therapeutic activity for the reduction of macular edema. At present, intraocular anti-TNF-α drugs do not show promising results. As regards nonsteroidal anti-inflammatory drugs, further data are necessary to fully understand their efficacy and potential side effects.

Original languageEnglish
Title of host publicationDevelopments in Ophthalmology
PublisherS. Karger AG
Number of pages12
ISBN (Print)9783805599870, 9783805599863
Publication statusPublished - Apr 20 2012

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Intravitreal injection therapy in the treatment of noninfectious uveitis'. Together they form a unique fingerprint.

Cite this